AR122721A1 - Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413 - Google Patents

Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413

Info

Publication number
AR122721A1
AR122721A1 ARP210101733A ARP210101733A AR122721A1 AR 122721 A1 AR122721 A1 AR 122721A1 AR P210101733 A ARP210101733 A AR P210101733A AR P210101733 A ARP210101733 A AR P210101733A AR 122721 A1 AR122721 A1 AR 122721A1
Authority
AR
Argentina
Prior art keywords
serine
affinity antibodies
antibodies directed
tau phosphorylated
antigen
Prior art date
Application number
ARP210101733A
Other languages
English (en)
Inventor
Jeanne E Bake
Batteur Sophie Parmentier
Ming Chen
- Cheng Alan C Tang
Chung Hsieh
- Mieczkowski Carl Ming
Sokreine Suon
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR122721A1 publication Critical patent/AR122721A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

En el presente documento se proporcionan anticuerpos de alta afinidad o fragmentos de unión a antígeno de los mismos que se unen específicamente a tau-pS413 humana. También se proporcionan composiciones, kits, métodos y usos en los que están implicados tales anticuerpos o fragmentos de unión a antígeno de los mismos.
ARP210101733A 2020-06-25 2021-06-23 Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413 AR122721A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063044291P 2020-06-25 2020-06-25

Publications (1)

Publication Number Publication Date
AR122721A1 true AR122721A1 (es) 2022-09-28

Family

ID=76959092

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101733A AR122721A1 (es) 2020-06-25 2021-06-23 Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413

Country Status (18)

Country Link
US (2) US20230265175A1 (es)
EP (1) EP4171633A1 (es)
JP (1) JP2023528535A (es)
KR (1) KR20230023802A (es)
CN (1) CN116723856A (es)
AR (1) AR122721A1 (es)
AU (1) AU2021297873A1 (es)
BR (1) BR112022026575A2 (es)
CA (1) CA3183835A1 (es)
CL (1) CL2022003723A1 (es)
CO (1) CO2022018547A2 (es)
DO (1) DOP2022000295A (es)
EC (1) ECSP23003930A (es)
IL (1) IL299292A (es)
MX (1) MX2022016322A (es)
PE (1) PE20230840A1 (es)
TW (1) TW202216759A (es)
WO (1) WO2021262791A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN117003863A (zh) * 2022-04-28 2023-11-07 厦门大学 针对p-tau 217的抗体及其用途

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
WO1997034145A1 (fr) 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
DE69942671D1 (de) 1998-12-01 2010-09-23 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
NZ512185A (en) 1998-12-09 2004-02-27 Dow Chemical Co A method for manufacturing glycoproteins having human- type glycosylation in plant cells
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
PT1914244E (pt) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
DE60139720D1 (de) 2000-06-28 2009-10-08 Glycofi Inc Verfahren für die Herstellung modifizierter Glykoproteine
US7632983B2 (en) 2000-07-31 2009-12-15 Biolex Therapeutics, Inc. Expression of monoclonal antibodies in duckweed
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
JPWO2003085107A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 ゲノムが改変された細胞
WO2003086310A2 (en) 2002-04-12 2003-10-23 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
WO2005120571A2 (en) 2004-06-07 2005-12-22 Ramot At Tel Aviv University Ltd. Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation
US7875278B2 (en) 2005-02-18 2011-01-25 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20070280935A1 (en) 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
EP1876185A1 (en) 2006-07-04 2008-01-09 F. Hoffmann-La Roche Ag An antibody which recognizes phosphorylated polypeptides
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CA2765099A1 (en) 2009-06-10 2010-12-16 New York University Phosphorylated tau peptide for use in the treatment of tauopathy
DK2462161T3 (en) 2009-08-06 2017-06-06 Immunas Pharma Inc Antibodies specifically binding to A-beta oligomers and their use
EP2560681A4 (en) 2010-04-22 2013-09-25 Janssen Alzheimer Immunotherap USE OF TAU FOR MONITORING IMMUNOTHERAPY
CN103502272B (zh) 2010-10-07 2016-06-15 Ac免疫有限公司 识别Tau的磷酸化特异抗体
SI2627672T1 (sl) 2010-10-11 2018-10-30 Biogen International Neuroscience Gmbh Človeška protitelesa anti-tau
CA2826286C (en) 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
MY186066A (en) 2011-12-20 2021-06-18 Janssen Biotech Inc Anti-phf-tau antibodies and their uses
US20150183854A1 (en) 2012-05-31 2015-07-02 Teijin Pharma Limited Therapeutic agent or prophylactic agent for dementia
BR112015003326A2 (pt) 2012-08-16 2017-07-04 Ipierian Inc métodos de tratamento de uma tauopatia
PT2935326T (pt) 2012-12-21 2020-09-14 Biogen Ma Inc Anticorpos anti-tau humanos
EP2989665B1 (en) 2013-04-25 2020-09-23 Lumileds Holding B.V. A light emitting diode component
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
WO2016112078A2 (en) 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
NZ738058A (en) 2015-07-06 2021-07-30 UCB Biopharma SRL Tau-binding antibodies
CN107849105B (zh) 2015-07-06 2021-09-17 Ucb生物制药有限责任公司 Tau结合抗体
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
JOP20180014A1 (ar) * 2017-02-27 2019-01-30 Teijin Pharma Ltd جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه

Also Published As

Publication number Publication date
DOP2022000295A (es) 2023-02-15
CO2022018547A2 (es) 2022-12-30
PE20230840A1 (es) 2023-05-19
ECSP23003930A (es) 2023-07-31
MX2022016322A (es) 2023-01-24
US20230167168A9 (en) 2023-06-01
JP2023528535A (ja) 2023-07-04
IL299292A (en) 2023-02-01
CL2022003723A1 (es) 2023-05-19
KR20230023802A (ko) 2023-02-17
US11702467B2 (en) 2023-07-18
WO2021262791A1 (en) 2021-12-30
BR112022026575A2 (pt) 2023-01-17
CA3183835A1 (en) 2021-12-30
TW202216759A (zh) 2022-05-01
CN116723856A (zh) 2023-09-08
EP4171633A1 (en) 2023-05-03
US20230265175A1 (en) 2023-08-24
US20210403541A1 (en) 2021-12-30
AU2021297873A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
DOP2022000295A (es) Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
CL2019002310A1 (es) Receptores quiméricos y métodos de uso de los mismos (divisional solicitud 201802797)
CL2021000517A1 (es) Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)
UY36751A (es) Anticuerpos de factor xi y métodos de uso
CL2021002696A1 (es) Anticuerpos anti-ige (divisional de solicitud 201803556)
UY37030A (es) Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
BR112019005316A2 (pt) anticorpos monoclonais para morte programada 1 (pd-1)
BR112022001368A2 (pt) Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
BR112017014308A2 (pt) anticorpos biespecíficos contra calicreína plasmática e fator xii
CL2021002039A1 (es) Agentes de unión a c3 y métodos para su uso (divisional de la solicitud n° 202002522)
UY39135A (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRAEL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
BR112022009723A2 (pt) Anticorpos específicos para cd47, pd-l1, e usos dos mesmos
ECSP17080733A (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos
BR112021026089A2 (pt) Fragmentos de ligação ao antígeno de cd3 e composições compreendendo os mesmos
BR112021017801A2 (pt) Anticorpos biespecíficos anti-vbeta17/anti-cd123
CO2022018537A2 (es) Agentes de unión a lair-1 y métodos para su uso
CL2021001607A1 (es) Anticuerpos anti-pmel17 y conjugados de los mismos
CO2023017156A2 (es) Anticuerpos anti-sirp-alfa
DOP2023000005A (es) Anticuerpos anti-betacelulina, fragmentos de los mismos, y moléculas de unión multiespecíficas
ECSP22004680A (es) Anticuerpos anti-angpt2
AR110424A1 (es) Moléculas de unión a adam9 y métodos de uso de las mismas
CL2021002501A1 (es) Compuestos novedosos y métodos de uso de los mismos.
CL2023001509A1 (es) Anticuerpos multiespecíficos y combinaciones de anticuerpos
BR112023021256A2 (pt) Anticorpos humanos para artemina e métodos de uso dos mesmos